Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06164704 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps
A Phase 2 study, sponsored by Upstream Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT06164704 is a Phase 2 study that has completed, run by Upstream Bio. The registered enrollment target is 81 participants.
The verdict
NCT06164704, a Phase 2 study, has completed, sponsored by Upstream Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
The primary purpose of this study is to assess the effect of verekitug (UPB-101) on the endoscopically determined size and extend of nasal polyps in participants with chronic rhinosinusitis with nasal polyps (CRSwNP) and to assess the safety and tolerability of verekitug (UPB-101) compared to placebo.
Interventions
- DRUG Placebo
- DRUG Verekitug (UPB-101)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2023-12-18 |
| Est. Completion | 2025-07-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06164704
The ClinicalTrials.gov registry entry for NCT06164704 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Upstream Bio, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06164704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06164704 about?
NCT06164704 is a clinical study titled "A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps". The primary purpose of this study is to assess the effect of verekitug (UPB-101) on the endoscopically determined size and extend of nasal polyps in participants with chronic rhinosinusitis with nasal polyps (CRSwNP) and to assess the safety and tolerability of verekitug (UPB-101) compared to placeb...
What is the current status of trial NCT06164704?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2023-12-18. Estimated completion is 2025-07-22.
What interventions are being tested in trial NCT06164704?
The interventions under investigation include: Placebo (DRUG), Verekitug (UPB-101) (DRUG).
Who is sponsoring clinical trial NCT06164704?
This trial is sponsored by Upstream Bio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.